Agf Management LTD Incyte Corp Transaction History

Agf Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $230,497 - $271,420	4,076 New	4,076 $232,000
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $496,244 - $566,338	-8,590 Reduced 15.59%	46,499 $2.69 Million
Q2 2023 Aug 09, 2023	BUY	$60.95 - $75.51 $644,972 - $799,046	10,582 Added 23.78%	55,089 $3.43 Million
Q1 2023 May 03, 2023	BUY	$70.23 - $86.01 $46,422 - $56,852	661 Added 1.51%	44,507 $3.22 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $2.95 Million - $3.69 Million	43,846 New	43,846 $0

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Agf Management LTD, based on Form 13F filings with the SEC.

Stay updated on Agf Management LTD with notifications on news.